Related references
Note: Only part of the references are listed.CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
H. Frangoul et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Duchenne muscular dystrophy
Dongsheng Duan et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine
Nalinda B. Wasala et al.
EXPERT OPINION ON DRUG DISCOVERY (2020)
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Helena Costa Verdera et al.
MOLECULAR THERAPY (2020)
The promise and challenge of therapeutic genome editing
Jennifer A. Doudna
NATURE (2020)
Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy
A. Moretti et al.
NATURE MEDICINE (2020)
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Dan Wang et al.
CELL (2020)
With First CRISPR Trials, Gene Editing Moves Toward the Clinic
Tracy Hampton
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9
Ang Li et al.
MOLECULAR THERAPY (2020)
Micro-dystrophin AAV Vectors Made by Transient Transfection and Herpesvirus System Are Equally Potent in Treating mdx Mouse Muscle Disease
Chady H. Hakim et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Development of Novel Micro-dystrophins with Enhanced Functionality
Julian N. Ramos et al.
MOLECULAR THERAPY (2019)
Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy
Christopher E. Nelson et al.
NATURE MEDICINE (2019)
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Carsten T. Charlesworth et al.
NATURE MEDICINE (2019)
Unified energetics analysis unravels SpCas9 cleavage activity for optimal gRNA design
Dong Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes
Shayesteh R. Ferdosi et al.
NATURE COMMUNICATIONS (2019)
Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy (vol 3, pg 806, 2019)
Ana M. Moreno et al.
NATURE BIOMEDICAL ENGINEERING (2019)
Questions Answered and Unanswered by the First CRISPR Editing Study in a Canine Model of Duchenne Muscular Dystrophy
Nalinda B. Wasala et al.
HUMAN GENE THERAPY (2019)
High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population
Dimitrios L. Wagner et al.
NATURE MEDICINE (2019)
Immunity to CRISPR Cas9 and Cas12a therapeutics
Wei Leong Chew
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE (2018)
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Dongsheng Duan
MOLECULAR THERAPY (2018)
RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors
Pratiksha I. Thakore et al.
NATURE COMMUNICATIONS (2018)
Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy
Leonela Amoasii et al.
SCIENCE (2018)
Cas9 immunity creates challenges for CRISPR gene editing therapies
Julie M. Crudele et al.
NATURE COMMUNICATIONS (2018)
AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice
Chady H. Hakim et al.
JCI INSIGHT (2018)
Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy
Leonela Amoasii et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
PABPN1 gene therapy for oculopharyngeal muscular dystrophy
A. Malerba et al.
NATURE COMMUNICATIONS (2017)
Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy
Niclas E. Bengtsson et al.
NATURE COMMUNICATIONS (2017)
Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape
Federico Mingozzi et al.
ANNUAL REVIEW OF VIROLOGY, VOL 4 (2017)
The golden retriever model of Duchenne muscular dystrophy
Joe N. Kornegay
SKELETAL MUSCLE (2017)
A Five-Repeat Micro-Dystrophin Gene Ameliorated Dystrophic Phenotype in the Severe DBA/2J-mdx Model of Duchenne Muscular Dystrophy
Chady H. Hakim et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Christopher E. Nelson et al.
SCIENCE (2016)
A multifunctional AAV-CRISPR-Cas9 and its host response
Wei Leong Chew et al.
NATURE METHODS (2016)
Systemic delivery of adeno-associated viral vectors
Dongsheng Duan
CURRENT OPINION IN VIROLOGY (2016)
Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy
Joe W. McGreevy et al.
DISEASE MODELS & MECHANISMS (2015)
Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses
Dan Wang et al.
HUMAN GENE THERAPY (2015)
Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus
Yongping Yue et al.
HUMAN MOLECULAR GENETICS (2015)
A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy
Jerry R. Mendell et al.
MOLECULAR THERAPY (2015)
Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases
Sangsu Bae et al.
BIOINFORMATICS (2014)
Characterization of 65 Epitope-Specific Dystrophin Monoclonal Antibodies in Canine and Murine Models of Duchenne Muscular Dystrophy by Immunostaining and Western Blot
Kasun Kodippili et al.
PLOS ONE (2014)
Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression
Christian Mueller et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran et al.
NATURE PROTOCOLS (2013)
An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed
Bruce F. Smith et al.
LABORATORY INVESTIGATION (2011)
Muscle satellite cells from GRMD dystrophic dogs are not phenotypically distinguishable from wild type satellite cells in ex vivo culture
Zachary Berg et al.
NEUROMUSCULAR DISORDERS (2011)
Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs
Deborah M. Fine et al.
NEUROMUSCULAR DISORDERS (2011)
A Single Intravenous Injection of Adeno-associated Virus Serotype-9 Leads to Whole Body Skeletal Muscle Transduction in Dogs
Yongping Yue et al.
MOLECULAR THERAPY (2008)
Methods of testing for a deficit in single-case studies: Evaluation of statistical power by Monte Carlo simulation
John R. Crawford et al.
COGNITIVE NEUROPSYCHOLOGY (2006)
An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers
Philip J. Smith et al.
HUMAN MOLECULAR GENETICS (2006)
Testing for a deficit in single-case studies: Effects of departures from normality
JR Crawford et al.
NEUROPSYCHOLOGIA (2006)
Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart
YP Yue et al.
CIRCULATION (2003)
ESEfinder: a web resource to identify exonic splicing enhancers
L Cartegni et al.
NUCLEIC ACIDS RESEARCH (2003)
The human genome browser at UCSC
WJ Kent et al.
GENOME RESEARCH (2002)
Share Paper
